CN103228792A - PEG-干扰素λ1结合物 - Google Patents

PEG-干扰素λ1结合物 Download PDF

Info

Publication number
CN103228792A
CN103228792A CN2012800033678A CN201280003367A CN103228792A CN 103228792 A CN103228792 A CN 103228792A CN 2012800033678 A CN2012800033678 A CN 2012800033678A CN 201280003367 A CN201280003367 A CN 201280003367A CN 103228792 A CN103228792 A CN 103228792A
Authority
CN
China
Prior art keywords
ifn
peg
binding substances
alkyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800033678A
Other languages
English (en)
Chinese (zh)
Inventor
何南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanogen Pharmaceutical Biotechnology
Original Assignee
Nanogen Pharmaceutical Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogen Pharmaceutical Biotechnology filed Critical Nanogen Pharmaceutical Biotechnology
Publication of CN103228792A publication Critical patent/CN103228792A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2012800033678A 2011-08-25 2012-03-01 PEG-干扰素λ1结合物 Pending CN103228792A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
VN1-2011-02222 2011-08-25
VN201102222 2011-08-25
PCT/US2012/027317 WO2013028233A1 (en) 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates

Publications (1)

Publication Number Publication Date
CN103228792A true CN103228792A (zh) 2013-07-31

Family

ID=47746747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012800033678A Pending CN103228792A (zh) 2011-08-25 2012-03-01 PEG-干扰素λ1结合物

Country Status (9)

Country Link
EP (1) EP2748328A4 (enrdf_load_stackoverflow)
JP (1) JP2014525939A (enrdf_load_stackoverflow)
CN (1) CN103228792A (enrdf_load_stackoverflow)
AU (1) AU2012299423A1 (enrdf_load_stackoverflow)
BR (1) BR112014004302A2 (enrdf_load_stackoverflow)
CA (1) CA2846092A1 (enrdf_load_stackoverflow)
RU (1) RU2014111179A (enrdf_load_stackoverflow)
WO (1) WO2013028233A1 (enrdf_load_stackoverflow)
ZA (1) ZA201401159B (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111065405A (zh) * 2017-09-08 2020-04-24 科学未来管理有限责任公司 口服生物利用度高的聚乙二醇化干扰素λ及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3416675T3 (pl) * 2016-02-19 2021-10-11 Eiger Biopharmaceuticals, Inc. Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda
ES3015227T3 (en) 2017-03-16 2025-04-30 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
CN112245570A (zh) 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
KR20230157947A (ko) 2021-01-21 2023-11-17 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 암 재발 방지를 위한 방법 및 약제학적 조합
KR20230157313A (ko) 2021-01-21 2023-11-16 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 인터페론-기반 암 치료 방법 및 약제학적 조합
WO2024121424A1 (en) 2022-12-09 2024-06-13 Daniel Zagury Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1381512A (zh) * 2002-01-15 2002-11-27 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
CN1927388A (zh) * 2004-09-10 2007-03-14 北京金迪克生物技术研究所 含有人干扰素的药物组合物
CN101002942A (zh) * 2007-01-08 2007-07-25 湖南大学 一种peg化脂质体纳米颗粒
US20080096252A1 (en) * 2005-10-04 2008-04-24 Zamost Bruce L Production and purification of il-29
US20080132681A1 (en) * 2005-06-03 2008-06-05 Ambrx, Inc. Human Interferon Molecules and Their Uses
CN102099051A (zh) * 2008-06-05 2011-06-15 津莫吉尼蒂克斯公司 利用聚乙二醇化的iii型干扰素治疗丙型肝炎

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1381512A (zh) * 2002-01-15 2002-11-27 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
CN1927388A (zh) * 2004-09-10 2007-03-14 北京金迪克生物技术研究所 含有人干扰素的药物组合物
US20080132681A1 (en) * 2005-06-03 2008-06-05 Ambrx, Inc. Human Interferon Molecules and Their Uses
US20080096252A1 (en) * 2005-10-04 2008-04-24 Zamost Bruce L Production and purification of il-29
US20100003722A1 (en) * 2005-10-04 2010-01-07 Zymogenetics, Llc Production and purification of il-29
CN101002942A (zh) * 2007-01-08 2007-07-25 湖南大学 一种peg化脂质体纳米颗粒
CN102099051A (zh) * 2008-06-05 2011-06-15 津莫吉尼蒂克斯公司 利用聚乙二醇化的iii型干扰素治疗丙型肝炎

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHEPPARD, P. ET AL.: "Accession NO：NP_742152，interleukin-29 precursor [Homo sapiens]", 《GENBANK DATABASE》, 21 August 2011 (2011-08-21) *
胡小剑等: "羧甲基化单甲氧基聚乙二醇的制备及其对a-干扰素的修饰", 《过程工程学报》, vol. 3, no. 2, 30 April 2003 (2003-04-30) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111065405A (zh) * 2017-09-08 2020-04-24 科学未来管理有限责任公司 口服生物利用度高的聚乙二醇化干扰素λ及其制备方法

Also Published As

Publication number Publication date
RU2014111179A (ru) 2015-09-27
BR112014004302A2 (pt) 2017-06-20
JP2014525939A (ja) 2014-10-02
EP2748328A1 (en) 2014-07-02
EP2748328A4 (en) 2015-03-04
AU2012299423A1 (en) 2014-03-06
CA2846092A1 (en) 2013-02-28
ZA201401159B (en) 2015-04-29
WO2013028233A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
US8980245B2 (en) PEG-interferon λ1 conjugates and methods of treating viral infections
JP2980569B2 (ja) インターフェロン複合体
CN103228792A (zh) PEG-干扰素λ1结合物
KR20020007296A (ko) Ｇｃｓｆ 결합체
HUT75533A (en) Improved interferon polymer conjugates
UA79430C2 (en) Method for the stepwise attachment of polyethylene glycol to polypeptide
WO2012011836A1 (en) The new stable polyethylene glycol conjugate of interferon alpha, represented by one positional isomer
CN103923209B (zh) 一种Lambda干扰素突变体及聚乙二醇衍生物
EP2272875A1 (en) Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
CN105085658A (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
CN101367872B (zh) 蛋白质-聚合物缀合物
KR100353392B1 (ko) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
CN105085657A (zh) 一种干扰素突变体及聚乙二醇衍生物
KR100888371B1 (ko) 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
CN103933577B (zh) 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
RU2466138C1 (ru) Конъюгаты интерферонов и способ их получения
WO2013029062A1 (en) Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
BRPI0804889B1 (pt) Processo de produção de conjugados de interferon com óxidos de polialquilenos e seus usos
HK1005225B (en) Interferon conjugates
MXPA97004012A (en) Conjugados de interfe

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130731